Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.54 |
| ▸ | RARB | P10826 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21558710 | 0.97 | LPL (0.55) | LPLLIPGRARBCA1CA2 | |
| SCHEMBL21558282 | 0.93 | LPL (0.51) | LPLLIPGRARBCA1CA2 | |
| SCHEMBL18365038 | 0.93 | LPL (0.51) | LPLLIPGRARBCA1CA2 | |
| SCHEMBL14302548 | 0.92 | LPL (0.61) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4515280 | 0.92 | CA1 (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1574216 | 0.92 | CA1 (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18727880 | 0.89 | LPL (0.62) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16790069 | 0.88 | LPL (0.56) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL15037360 | 0.88 | LPL (0.63) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25527190 | 0.88 | LPL (0.63) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | Wuxi Life Fountain Biotech Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-3988098-A1 | HETEROCYCLO ALKYL COMPOUNDS USED AS CCR2/CCR5 ANTAGONIST | Shenzhen Lingfang Biotech Co., Ltd (CN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3567028-B1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | MEDSHINE DISCOVERY INC (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| CN-113412261-A | Benzimidazole compounds, preparation method and use thereof | 四川科伦博泰生物医药股份有限公司 | 2021-09-17 | — | — | CN | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3567028-A1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | LPL 3048/4885LIPG 2878/4885RARB 304/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | LPL 3048/4885LIPG 2878/4885RARB 304/4885 |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | CCR2, CCR5, CCRL2 | LPL 3610/4885LIPG 3531/4885RARB 1640/4885 |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | LPL 1168/4885LIPG 2475/4885RARB 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.